Publications

  1. Victorson DE, Brucker PS, Bode RK, Eton DT, Talcott JA, Clark JA, Knight SJ, Litwin MS, Moinpour CM, Reeve BB, Aaronson NK, Bennett CL, Herr HW, McGuire M, Shevrin D, McVary K, Cella D. Ensuring comprehensive assessment of urinary problems in prostate cancer through patient-physician concordance. Urol Oncol. 2013 Mar 20. [Epub ahead of print] 2319876
    View PubMed
  2. Yost KJ, Thompson CA, Eton DT, Allmer C, Ehlers SL, Habermann TM, Shanafelt TD, Maurer MJ, Slager SL, Link BK, Cerhan JR. The Functional Assessment of Cancer Therapy - General (FACT-G) is valid for monitoring quality of life in patients with non-Hodgkin lymphoma. Leuk Lymphoma. 2013 Feb; 54(2):290-7. Epub 2012 Sep 06. 2280842
    View PubMed
  3. Rank MA, Ziegenfuss JY, Shah KM, Jenkins SM, Lackore KA, Eton DT, Shah ND. Factors associated with decisions to step down asthma medications. Journal of Allergy and Clinical Immunology: In Practice. 2013; 1(3):312-4. 2324449
  4. Gallacher K, Bhautesh J, Deborah M, Sara M, David B, Patricia E, R MC, M MV, T ED, Fiona S, David BG, S MF, International Minimally Disruptive Medicine Workgroup. Qualitative systematic reviews of treatment burden in stroke, heart failure and diabetes - methodological challenges and solutions. BMC Med Res Methodol. 2013; 13:10. Epub 2013 Jan 28. 2311832
    View PubMed
  5. Suri RM, Antiel RM, Burkhart HM, Huebner M, Li Z, Eton DT, Topilsky T, Sarano ME, Schaff HV. Quality of life after early mitral valve repair using conventional and robotic approaches. Ann Thorac Surg. 2012 Mar; 93(3):761-9. 2227631
    View PubMed
  6. Tran VT, Montori VM, Eton DT, Baruch D, Falissard B, Ravaud P. Development and description of measurement properties of an instrument to assess treatment burden among patients with multiple chronic conditions. BMC Med. 2012; 10:68. Epub 2012 Jul 04. 2218682
    View PubMed
  7. Eton DT, Ramalho de Oliveira D, Egginton JS, Ridgeway JL, Odell L, May CR, Montori VM. Building a measurement framework of burden of treatment in complex patients with chronic conditions: a qualitative study. Patient Relat Outcome Meas. 2012; 3:39-49. Epub 2012 Aug 24. 2249499
    View PubMed
  8. Eton DT, Bauer BA, Sood A, Yost KJ, Sloan JA. Patient-reported outcomes in studies of complementary and alternative medicine: problems, solutions, and future directions. Explore (NY). 2011 Sep-Oct; 7(5):314-9. 2189364
    View PubMed
  9. Yost KJ, Eton DT, Garcia SF, Cella D. Minimally important differences were estimated for six Patient-Reported Outcomes Measurement Information System-Cancer scales in advanced-stage cancer patients. J Clin Epidemiol. 2011 May; 64(5):507-16. 2155672
    View PubMed
  10. Eton DT, Cella D. Do erythropoietic-stimulating agents relieve fatigue? A review of reviews. Cancer Treat Res. 2011; 157:181-94. 2124171
    View PubMed
  11. Tilburt JC, James KM, Sinicrope PS, Eton DT, Costello BA, Carey J, Lane MA, Ehlers SL, Erwin PJ, Nowakowski KE, Murad MH. Factors influencing cancer risk perception in high risk populations: a systematic review. Hered Cancer Clin Pract. 2011; 9:2. Epub 2011 May 19. 2172280
    View PubMed
  12. Eton DT, Shevrin DH, Beaumont J, Victorson D, Cella D. Constructing a conceptual framework of patient-reported outcomes for metastatic hormone-refractory prostate cancer. Value Health. 2010 Aug; 13(5):613-23. Epub 2010 Mar 10. 1992907
    View PubMed
  13. King MT, Cella D, Osoba D, Stockler M, Eton D, Thompson J, Eisenstein A. Meta-analysis provides evidence-based interpretation guidelines for the clinical significance of mean differences for the FACT-G, a cancer-specific quality of life questionnaire. Patient Relat Outcome Meas. 2010 Jul; 1:119-26. Epub 2010 Sep 23. 2114187
    View PubMed
  14. Lai JS, Bode R, Wee HL, Eton D, Cella D. A brief assessment of physical functioning for prostate cancer patients. Patient Relat Outcome Meas. 2010 Jul; 1:51-6. Epub 2010 Jun 18. 1991429
    View PubMed
  15. King MT, Stockler MR, Cella DF, Osoba D, Eton DT, Thompson J, Eisenstein AR. Meta-analysis provides evidence-based effect sizes for a cancer-specific quality-of-life questionnaire, the FACT-G. J Clin Epidemiol. 2010 Mar; 63(3):270-81. Epub 2009 Aug 27. 1988023
    View PubMed
  16. Broom R, Du H, Clemons M, Eton D, Dranitsaris G, Simmons C, Ooi W, Cella D. Switching breast cancer patients with progressive bone metastases to third-generation bisphosphonates: measuring impact using the Functional Assessment of Cancer Therapy-Bone Pain. J Pain Symptom Manage. 2009 Aug; 38(2):244-57. Epub 2009 Apr 11. 1981872
    View PubMed
  17. Cella D, Nichol MB, Eton D, Nelson JB, Mulani P. Estimating clinically meaningful changes for the Functional Assessment of Cancer Therapy--Prostate: results from a clinical trial of patients with metastatic hormone-refractory prostate cancer. Value Health. 2009 Jan; 12(1):124-9. Epub 2008 Jul 18. 1944457
    View PubMed
  18. Cella D, Eton D, Hensing TA, Masters GA, Parasuraman B. Relationship between symptom change, objective tumor measurements, and performance status during chemotherapy for advanced lung cancer. Clin Lung Cancer. 2008 Jan; 9(1):51-8. 1951057
    View PubMed
  19. Thompson I, Thrasher JB, Aus G, Burnett AL, Canby-Hagino ED, Cookson MS, D'Amico AV, Dmochowski RR, Eton DT, Forman JD, Goldenberg SL, Hernandez J, Higano CS, Kraus SR, Moul JW, Tangen CM, AUA Prostate Cancer Clinical Guideline Update Panel. Guideline for the management of clinically localized prostate cancer: 2007 update. J Urol. 2007 Jun; 177(6):2106-31. 2148839
    View PubMed
  20. Burnett AL, Aus G, Canby-Hagino ED, Cookson MS, D’Amico AV, Dmochowski RR, Eton DT, Forman JD, Goldenberg SL, Hernandez J, Higano CS, Kraus S, Liebert M, Moul JW, Tangen C, Thrasher JB, Thompson I, American Urological Association Prostate Cancer Gui Erectile function outcome reporting after clinically localized prostate cancer treatment. Journal of Urology. 2007; 178:597-601. 1944461
  21. Cookson MS, Aus G, Burnett AL, Canby-Hagino ED, D’Amico AV, Dmochowski RR, Eton DT, Forman JD, Goldenberg SL, Hernandez J, Higano CS, Kraus SR, Moul JW, Tangen C, Thrasher, JB, Thompson I. Variation in the definition of biochemical recurrence in patients treated for localized prostate cancer: The American Urological Association Prostate Guidelines for Localized Prostate Cancer Update Panel Report and Recommendations for a Standard in the Re porting of Surgical Outcomes. Journal of Urology. 2007; 7:540-545. 1944462
  22. Davis K, Yount SE, Del Ciello K, Whalen M, Khan S, Bass M, Du H, Eton DT, Masters G, Hensing T, Cella D. An innovative symptom monitoring tool for people with advanced lung cancer: A pilot demonstration. Journal of Supportive Oncology. 2007; 5:381-87. 1944463
  23. Eton DT, Cella, Yount SE, Davis KM. Validation of the Functional Assessment of Cancer Therapy-Lung Symptom Index – 12 (FLSI-12). Lung Cancer. 2007; 57:339-47. 1944455
  24. Eton DT, Mendoza Temple L, Koffler K. Pilot validation of a self-report outcome measure of complementary and alternative medicine. Explore: The Journal of Science & Healing. 2007; 3:592-99. 1944456
  25. Eton DT, Yost KJ, Cella D. Future trends in patient-reported outcomes assessment for patients with advanced-stage lung cancer receiving targeted therapy. Clin Lung Cancer. 2006 Sep; 8(2):99-109. 1943309
    View PubMed
  26. Darling G, Eton DT, Sulman J, Casson AG, Celia D. Validation of the functional assessment of cancer therapy esophageal cancer subscale. Cancer. 2006 Aug 15; 107(4):854-63. 1944452
    View PubMed
  27. Helgeson VS, Lepore SJ, Eton DT. Moderators of the benefits of psychoeducational interventions for men with prostate cancer. Health Psychol. 2006 May; 25(3):348-54. 1944451
    View PubMed
  28. Steel JL, Eton DT, Cella D, Olek MC, Carr BI. Clinically meaningful changes in health-related quality of life in patients diagnosed with hepatobiliary carcinoma. Ann Oncol. 2006 Feb; 17(2):304-12. Epub 2005 Dec 15. 1944450
    View PubMed
  29. Eton DT, Cella D, Bacik J, Motzer RJ. A brief symptom index for advanced renal cell carcinoma. Health & Quality of Life Outcomes. 2006; 4:68. 1944453
  30. Yost KJ, Cella D, Chawla A, Holmgren E, Eton DT, Ayanian JZ, West DW. Minimally important differences were estimated for the Functional Assessment of Cancer Therapy-Colorectal (FACT-C) instrument using a combination of distribution- and anchor-based approaches. J Clin Epidemiol. 2005 Dec; 58(12):1241-51. Epub 2005 Oct 13. 1943311
    View PubMed
  31. Eton DT, Lepore SJ, Helgeson VS. Psychological distress in spouses of men treated for early-stage prostate carcinoma. Cancer. 2005 Jun 1; 103(11):2412-8. 1944449
    View PubMed
  32. Yost KJ, Eton DT. Combining distribution- and anchor-based approaches to determine minimally important differences: the FACIT experience. Eval Health Prof. 2005 Jun; 28(2):172-91. 1943313
    View PubMed
  33. Yost KJ, Yount SE, Eton DT, Silberman C, Broughton-Heyes A, Cella D. Validation of the Functional Assessment of Cancer Therapy-Breast Symptom Index (FBSI). Breast Cancer Res Treat. 2005 Apr; 90(3):295-8. 1943315
    View PubMed
  34. Eton DT, Lai J-s, Cella D, Reeve BB, Talcott JA, Clark JA, McPherson CP, Litwin MS, Moinpour CM. Data pooling and analysis to build a preliminary item bank: An example using bowel function in prostate cancer. Evaluation & the Health Professions. 2005; 28:142-159. 1944447
  35. Eton DT, Koffler K, Cella D, Eisenstein A, Astin JA, Pelletier KR, Riley D. Developing a self-report outcome measure for complementary and alternative medicine. Explore: Journal of Science & Healing. 2005; 1:177-185. 1944448
  36. Eton DT, Cella D, Yost KJ, Yount SE, Peterman AH, Neuberg DS, Sledge GW, Wood WC. A combination of distribution- and anchor-based approaches determined minimally important differences (MIDs) for four endpoints in a breast cancer scale. J Clin Epidemiol. 2004 Sep; 57(9):898-910. 1943317
    View PubMed
  37. Helgeson VS, Novak SA, Lepore SJ, Eton DT. Spouse social control efforts: Relations to health behavior and well-being among men with prostate cancer. Journal of Social & Personal Relationships. 2004; 21:53-68. 1944446
  38. Lepore SJ, Helgeson VS, Eton DT, Schulz R. Improving quality of life in men with prostate cancer: a randomized controlled trial of group education interventions. Health Psychol. 2003 Sep; 22(5):443-52. 1944444
    View PubMed
  39. Eton DT, Fairclough DL, Cella D, Yount SE, Bonomi P, Johnson DH, Eastern Cooperative Oncology Group. Early change in patient-reported health during lung cancer chemotherapy predicts clinical outcomes beyond those predicted by baseline report: results from Eastern Cooperative Oncology Group Study 5592. J Clin Oncol. 2003 Apr 15; 21(8):1536-43. 2148811
    View PubMed
  40. Cella D, Eton DT, Lai JS, Peterman AH, Merkel DE. Combining anchor and distribution-based methods to derive minimal clinically important differences on the Functional Assessment of Cancer Therapy (FACT) anemia and fatigue scales. J Pain Symptom Manage. 2002 Dec; 24(6):547-61. 2148808
    View PubMed
  41. Eton DT, Lepore SJ. Prostate cancer and health-related quality of life: a review of the literature. Psychooncology. 2002 Jul-Aug; 11(4):307-26. 1944443
    View PubMed
  42. Cella D, Eton DT, Fairclough DL, Bonomi P, Heyes AE, Silberman C, Wolf MK, Johnson DH. What is a clinically meaningful change on the Functional Assessment of Cancer Therapy-Lung (FACT-L) Questionnaire? Results from Eastern Cooperative Oncology Group (ECOG) Study 5592. J Clin Epidemiol. 2002 Mar; 55(3):285-95. 1944441
    View PubMed
  43. Eton DT, Lepore SJ, Helgeson VS. Early quality of life in patients with localized prostate carcinoma: an examination of treatment-related, demographic, and psychosocial factors. Cancer. 2001 Sep 15; 92(6):1451-9. 1944440
    View PubMed
  44. Wiener R, Eton D, Gibbons VP, Goldner JA, Johnson SH. A preliminary analysis of medical futility decisionmaking: Law and professional attitudes. Behavioral Sciences and the Law. 1998; 16:497-508. 1944467
  45. Eton DT, Gilner FH, Munz DC. The measurement of imagery vividness: A test of the reliability and validity of the Vividness of Visual Imagery Questionnaire and the Vividness of Movement Imagery Questionnaire Journal of Mental Imagery. 1998; 22:125-136. 1944468
  46. Johnson SH, Gibbons VP, Goldner JA, Wiener RL, Eton D. Legal and institutional policy responses to medical futility. Journal of Health and Hospital Law. 1997; 30:21-36. 1944466
  47. Eton DT, Elraiyah TA, Yost KJ, Ridgeway JL, Johnson A, Egginton JS, Mullan RJ, Murad MH, Erwin PJ, Montori VM. A systematic review of patient-reported measures of burden of treatment in three chronic disease. Patient Related Outcome Measures. In Press Epub 2013. 2314777